19 results on '"Long, G.V."'
Search Results
2. 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone.
3. LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial.
4. 1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047.
5. 1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma.
6. 740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results.
7. LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047.
8. 1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma.
9. 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma.
10. 817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047.
11. 797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm
12. 1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo).
13. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
14. 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL).
15. 1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047.
16. 1500P Health-related quality of life in melanoma patients treated with neoadjuvant nivolumab and domatinostat: Preliminary results.
17. 1106P International experience of ipilimumab and nivolumab in patients with advanced melanoma.
18. 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial.
19. 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.